IBD-what role do Proteobacteria play?

Nature Reviews Gastroenterology and Hepatology

Volumn 9, Issue 4, 2012, Pages 219-230

  Mukhopadhya, Indrani ^a   Hansen, Richard ^a   El Omar, Emad M ^a   Hold, Georgina L ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAPROTEOBACTERIA; AUTOPHAGY; BETAPROTEOBACTERIA; CAMPYLOBACTER; CROHN DISEASE; DELTAPROTEOBACTERIA; ENTERITIS; EPSILONPROTEOBACTERIA; ESCHERICHIA COLI; GAMMAPROTEOBACTERIA; GENE; GENETIC POLYMORPHISM; HELICOBACTER; HOST; HUMAN; INNATE IMMUNITY; INTESTINE FLORA; MICROBIAL DIVERSITY; NOD2 GENE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEOBACTERIA; REVIEW; ULCERATIVE COLITIS;

GASTROINTESTINAL TRACT; HUMANS; INFLAMMATORY BOWEL DISEASES; METAGENOME; PROTEOBACTERIA;

EID: 84859443151     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2012.14     Document Type: Review

References (152)

1. Hugot, J. P. et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411, 599-603 (2001).
2. Hugot, J. P. et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 379, 821-823 (1996).
3. Ogura.Y et al. Aframeshift mutation in N0D2 associated with susceptibility to Crohn's disease. Nature 411, 603-606 (2001).
4. Hampe, J. et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat. Genet. 39, 207-211 (2007). (Pubitemid 46184351)
5. Saitoh, T. et al. Loss of the autophagy protein Atgl6Ll enhances endotoxin-induced IL-ip production. Nature 456, 264-268 (2008).
6. Feller, M. et al. Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis. Lancet Infect. Dis. 7, 607-613 (2007). (Pubitemid 47268226)
7. Abubakar, I., Myhill, D., Aliyu.S. H. & Hunter, P. R. Detection of Mycobacterium avium subspecies paratuberculosis from patients with Crohn's disease using nucleic acid-based techniques: a systematic review and meta-analysis. Inflamm. Bowel Dis. 14, 401-410 (2008). (Pubitemid 351441331)
8. Mann, E. A. & Saeed, S. A. Gastrointestinal infection as a trigger for inflammatory bowel disease. Curr. Opin. Gastroenterol. 28, 24-29 (2012).
9. Willing, B. et al. Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. Inflamm. Bowel Dis. 15, 653-660 (2009).
10. Sokol, H. et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm. Bowel Dis. 15, 1183-1189 (2009).
11. Round, J. L. & Mazmanian, S. K. The gut microbiota shapes intestinal immune responses during health and disease. Nat. Rev. Immunol. 9, 313-323 (2009).
12. Tamboli, C. P., Neut, C, Desreumaux, P. & Colombel, J. F. Dysbiosis in inflammatory bowel disease. Gut 53, 1-4 (2004). (Pubitemid 38082999)
13. Joossens, M. et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut 60, 631-637 (2011).
14. Lupp, C. et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2, 119-129 (2007). (Pubitemid 47209521)
15. Barnich, N., Denizot, J. & Darfeuille-Michaud, A. E. coli-mediated gut inflammation in genetically predisposed Crohn's disease patients. Pathol. Biol. (Paris) http://dx.doi.org/10.1016/j.patbio.2010.01.004.
16. Boudeau, J., Glasser, A. L., Masseret, E., Joly, B. & Darfeuille-Michaud, A. Invasive ability of an Escherichia coli strain isolated from the ileal mucosa of a patient with Crohn's disease. Infect. Immun. 67, 4499-4509 (1999). (Pubitemid 29400425)
17. Darfeuille-Michaud, A. et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 127, 412-21(2004). (Pubitemid 39091889)
18. Darfeuille-Michaud, A. et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 115, 1405-1413 (1998). (Pubitemid 28545991)
19. Mahendran, V. et al. Prevalence of Campylobacter species in adult Crohn's disease and the preferential colonization sites of Campylobacter species in the human intestine. PLoS ONE 6, e25417 (2011).
20. Man.S. M. et al. Host attachment, invasion, and stimulation of proinflammatory cytokines by Campylobacter concisus and other non-Campylobacter jejuni Campylobacter species. J. Infect. Dis. 202, 1855-1865 (2010).
21. Mukhopadhya, I. et al. Detection of Campylobacter concisus and other Campylobacter species in colonic biopsies from adults with ulcerative colitis. PLoS ONE 6, e21490 (2011).
22. Zhang, L. et al. Detection and isolation of Campylobacter species other than C. jejuni from children with Crohn's disease. J. Clin. Microbiol. 47, 453-455(2009).
23. Kersters, K. et al. in The Prokaryotes (eds Falkow, S., Rosenberg, E., Schleifer, K.-H., Stackebrandt, E. & Dworkin, M.) 3-37 (Springer, New York, 2006).
24. Stackebrandt, E., Murray, R. G. E. & Truper, H. G. Proteobacteria classis nov., a name for the phylogenetic taxon that i ncl udes the " purple bacteria and their relatives". Int. J. Syst. Bacteriol. 38, 321-325 (1988).
25. Mignot, T. The elusive engine in Myxococcus xanthus gliding motility. Cell. Mol. Life Sci. 64, 2733-2745 (2007). (Pubitemid 351152260)
26. Swan, B. K. et al. Potential for chemolithoautotrophy among ubiquitous bacteria lineages in the dark ocean. Science 333, 1296-1300 (2011).
27. Bryant, D. A. & Frigaard, N. U. Prokaryotic photosynthesis and phototrophy illuminated. Trends Microbiol. 14, 488-96 (2006). (Pubitemid 44537806)
28. Vesteinsdottir, H., Reynisdottir, D. B. & Orlygsson, J. Thiomonas islandica sp. nov, a moderately thermophilic, hydrogen-and sulfur-oxidizing betaproteobacterium isolated from a hot spring. Int. J. Syst. Evol. Microbiol. 61, 132-137 (2011).
29. Irgens, R. L, Gosink, J. J. & Staley, J.T Polaromonas vacuolata gen. nov., sp. nov., a psychrophilic, marine, gas vacuolate bacterium from Antarctica. Int. J. Syst. Bacteriol. 46, 822-826 (1996).
30. Martin, W. & Muller, M. The hydrogen hypothesis for the first eukaryote. Nature 392, 37-1 (1998). (Pubitemid 28150580)
31. Singer, E. et al. Mariprofundus ferrooxydans PV-1 the first genome of a marine Fe(ll) oxidizing Zetaproteobacterium. PLoS ONE6, e25386 (2011).
32. Rehman.A. et al. Transcriptional activity of the dominant gut mucosal microbiota in chronic nflammatory bowel disease patients. J. Med. Microbiol. 59, 1114-1122 (2010).
33. Frank, D. N. et al. Molecular-phylogenetic characterization of microbial community mbalances in human inflammatory bowel diseases. Proc. Natl Acad. Sci. USA 104, 13780-13785 (2007). (Pubitemid 350003397)
34. Gophna, U., Sommerfeld, K., Gophna, S., Doolittle, W. F & Veldhuyzen van Zanten, S. J. Differences between tissue-associated intestinal microfloras of patients with Crohn's disease and ulcerative colitis. J. Clin. Microbiol. 44, 4136-141 (2006). (Pubitemid 44737260)
35. Dethlefsen, L, Huse, S., Sogin, M. L. & Relman, D. A. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 6, e280 (2008).
36. Khan, K. J. et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and metaanalysis. Am. J. Gastroenterol. 106, 661-673 (2011).
37. Massei, F, Massimetti, M., Messina, F, Macchia, P. & Maggiore, G. Bartonella henselae and inflammatory bowel disease. Lancet 356, 1245-1246 (2000).
38. Ventura, A. et al. Systemic Bartonella henselae nfection with hepatosplenic involvement. J. Pediatr. Gastroenterol. Nutr. 29, 52-56 (1999). (Pubitemid 30345828)
39. Baldwin, C. L. & Winter, A. J. Macrophages and Brucella. Immunol. Ser. 60, 363-380 (1994).
40. Musso, T. et al. Interaction of Bartonella henselae with the murine macrophage cell line J774: nfection and proinflammatory response. Infect Immun. 69, 5974-5980 (2001). (Pubitemid 32885155)
41. Sim, W. H. et al. Novel Burkholderiales 23S rRNA genes identified in ileal biopsy samples from children: preliminary evidence that a subtype is associated with perianal Crohn's disease. J. Clin. Microbiol. 48, 1939-1942 (2010).
42. Frank, D. N. et al. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm. Bowel Dis. 17, 179-184 (2011).
43. Walker, A. W. et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between nflamed and non-inflamed regions of the intestine n inflammatory bowel disease. BMC Microbiol. 11, 7 (2011).
44. Shulman, S. I, Friedmann, H. C. & Sims, R. H. Theodor Escherich: the first pediatric infectious diseases physician? Clin. Infect Dis. 45, 1025-1029 (2007).
45. Kaper, J. B., Nataro, J. P. & Mobley, H. L. Pathogenic Escherichia coli. Nat. Rev. Microbiol. 2, 123-140 (2004). (Pubitemid 39490066)
46. Rolhion, N. & Darfeuille-Michaud, A. Adherent-nvasive Escherichia coli in inflammatory bowel disease. Inflamm. Bowel Dis. 13, 1277-1283 (2007). (Pubitemid 47597778)
47. Tabaqchali, S., O'Donoghue, D. P. & Bettelheim, K. A. Escherichia coli antibodies in patients with inflammatory bowel disease. Gut 19, 108-113 (1978). (Pubitemid 8316085)
48. Swidsinski, A. et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 122, 44-54 (2002). (Pubitemid 34049193)
49. Martin, H. M. et al. Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology 127, 80-93 (2004). (Pubitemid 38962277)
50. Sepehri, S. et al. Characterization of Escherichia coli isolated from gut biopsies of newly diagnosed patients with inflammatory bowel disease. Inflamm. Bowel Dis. 17, 1451-1463 (2011).
51. Arnott, I. D. et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not N0D2/CARD15 genotype. Am. J. Gastroenterol. 99, 2376-2384 (2004). (Pubitemid 40039369)
52. Mow, W. S. et al. High-level serum antibodies to bacterial antigens are associated with antibiotic-nduced clinical remission in Crohn's disease: a pilot study. Dig. Dis. Sci. 49, 1280-1286 (2004). (Pubitemid 39178101)
53. Mow, W. S. et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 126, 414-424 (2004). (Pubitemid 38182298)
54. Beaven, S. W. & Abreu, M. T. Biomarkers in nflammatory bowel disease. Curr. Opin. Gastroenterol. 20, 318-327 (2004).
55. Landers, C. J. et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto-and microbial antigens. Gastroenterology 123, 689-699 (2002). (Pubitemid 34977074)
56. Rolhion, N., Carvalho, F. A. & Darfeuille-Michaud, A. OmpC and the sigma(E) regulatory pathway are involved in adhesion and invasion of the Crohn's disease-associated Escherichia coli strain LF82. Mol. Microbiol. 63, 1684-1700 (2007). (Pubitemid 46426710)
57. Giaffer, M. H., Holdsworth, C. D. & Duerden, B. I. Virulence properties of Escherichia coli strains isolated from patients with inflammatory bowel disease. Gut 33, 646-650 (1992).
58. Liu, Y. et al. Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology 108, 1396-1404 (1995).
59. Boudeau, J., Barnich, N. & Darfeuille-Michaud, A. Type 1 pili-mediated adherence of Escherichia coli strain LF82 isolated from Crohn's disease is nvolved in bacterial invasion of intestinal epithelial cells. Mol. Microbiol. 39, 1272-1284 (2001). (Pubitemid 32225137)
60. Barnich, N., Boudeau, J., Claret, L. & Darfeuille-Michaud, A. Regulatory and functional cooperation of flagella and type 1 pili in adhesive and invasive abilities of AIEC strain LF82 isolated from a patient with Crohn's disease. Mol. Microbiol. 48, 781-794 (2003). (Pubitemid 36819062)
61. Barnich, N. et al. CEACAM6 acts as a receptor for adherent-invasive, E. coli, supporting ileal mucosa colonization in Crohn disease. J. Clin. Invest 117, 1566-1574 (2007). (Pubitemid 46871341)
62. Kleessen.B., Kroesen.A. J., Buhr, H.J. & Blaut, M. Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. Scand.J. Gastroenterol. 37, 1034-1041 (2002).
63. Glasser, A. L. et al. Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without nducing host cell death. Infect Immun. 69, 5529-5537 (2001).
64. Chassaing, B. et al. Crohn disease-associated adherent-invasive E. coli bacteria target mouse and human Peyer's patches via long polar fimbriae. J. Clin. Invest 121, 966-975 (2011).
65. Meconi, S. et al. Adherent-invasive Escherichia coli isolated from Crohn's disease patients induce granulomas in vitro. Cell. Microbiol. 9, 1252-1261 (2007). (Pubitemid 46547142)
66. Simpson, K. W. et al. Adherent and invasive Escherichia coli is associated with granulomatous colitis in boxer dogs. Infect Immun. 74, 4778-4792 (2006). (Pubitemid 44157265)
67. Mansfield, C. S. et al. Remission of histiocytic ulcerative colitis in Boxer dogs correlates with eradication of invasive intramucosal Escherichia coli. J. Vet Intern. Med. 23, 964-969 (2009).
68. Nash, J. H. et al. Genome sequence of adherent-nvasive Escherichia coli and comparative genomic analysis with other, E. coli pathotypes. BMC Genomics 11, 667 (2010).
69. Miquel S. et al. Complete genome sequence of Crohn's disease-associated adherent-invasive E. coli strain LF82. PLoS ONE 5, el2714 (2010).
70. Garrett, W. S. et al. Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis. Cell Host Microbe 8, 292-300 (2010).
71. Lee, I. A. & Kim, D. H. Klebsiella pneumoniae ncreases the risk of inflammation and colitis in a murine model of intestinal bowel disease. Scand. J. Gastroenterol. 46, 684-693 (2011).
72. Gutierrez, A. et al. Cytokine association with bacterial DNA in serum of patients with nflammatory bowel disease. Inflamm. Bowel Dis. 15, 508-514 (2009).
73. Kang, S. et al. Dysbiosis of fecal microbiota in Crohn's disease patients as revealed by a custom phylogenetic microarray. Inflamm. Bowel Dis. 16, 2034-2042 (2010).
74. Lamps, L. W. et al. Pathogenic Yersinia DNA is detected in bowel and mesenteric lymph nodes from patients with Crohn's disease. Am. J. Surg. Pathol. 27, 220-227 (2003). (Pubitemid 36152232)
75. Zippi, M. et al. Mesenteric adenitis caused by Yersinia pseudotubercolosis in a patient subsequently diagnosed with Crohn's disease of the terminal ileum. World J. Gastroenterol. 12, 3933-3935 (2006). (Pubitemid 44028413)
76. Saebo, A., Vik, E., Lange, O. J. & Matuszkiewicz, L. Inflammatory bowel disease associated with Yersinia enterocolitica 0:3 infection. Eur. J. Intern. Med. 16, 176-182 (2005). (Pubitemid 40828255)
77. Safa, G., Loppin, M., Tisseau, L. & Lamoril, J. Cutaneous aseptic neutrophilic abscesses and Yersinia enterocolitica infection in a case subsequently diagnosed as Crohn's disease. Dermatology 217, 340-342 (2008).
78. Gradel, K. O. et al. Increased short-and long-term risk of inflammatory bowel disease after Salmonella or Campylobacter gastroenteritis. Gastroenterology 137, 495-501 (2009).
79. Jess, T. et al. Enteric Salmonella or Campylobacter nfections and the risk of inflammatory bowel disease. Gut 60, 318-324 (2010).
80. Parent, K. & Mitchell, P. Pseucfomonas-like group Va bacteria in Crohn's disease. Gastroenterology 75, 765 (1978).
81. Parent, K. & Mitchell, P. Cell wall-defective variants of Pseucfomonas-like (group Va) bacteria in Crohn's disease. Gastroenterology 75, 368-372 (1978). (Pubitemid 8389349)
82. Graham, D. Y, Yoshimura, H. H. & Estes, M. K. DNA hybridization studies of the association of Pseudomonas maltophilia with inflammatory bowel diseases. J. Lab. Clin. Med. 101, 940-954 (1983). (Pubitemid 13100689)
83. Wagner, J. et al. Identification and characterisation of Pseudomonas 16S ribosomal DNA from ileal biopsies of children with Crohn's disease. PLoS ONE 3, e3578 (2008).
84. Wei, B. et al. Pseudomonas fluorescens encodes the Crohn's disease-associated 12 sequence and T-cell superantigen. Infect Immun. 70, 6567-6575 (2002). (Pubitemid 35387882)
85. Sutton, C. L. et al. Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology 119, 23-31 (2000). (Pubitemid 30452575)
86. Suchodolski, J. S., Xenoulis, P. G., Paddock, C. G., Steiner, J. M. & Jergens, A. E. Molecular analysis of the bacterial microbiota in duodenal biopsies from dogs with idiopathic inflammatory bowel disease. Vet Microbiol. 142, 394-00 (2010).
87. Kangro, H. O., Chong, S. K., Hardiman.A., Heath, R. B. & Walker-Smith, J. A. A prospective study of viral and mycoplasma infections in chronic inflammatory bowel disease. Gastroenterology 98, 549-553 (1990). (Pubitemid 20069688)
88. Verma, R., Verma, A. K., Ahuja, V & Paul, J. Realtime analysis of mucosal flora in patients with nflammatory bowel disease in India. J. Clin. Microbiol. 48, 4279-282 (2010).
89. Duffy, M. et al. Sulfate-reducing bacteria colonize pouches formed for ulcerative colitis but not for familial adenomatous polyposis. Dis. Colon Rectum 45, 384-388 (2002). (Pubitemid 34273621)
90. Pitcher, M. C. & Cummings, J. H. Hydrogen sulphide: a bacterial toxin in ulcerative colitis? Gut 39, 1-4 (1996). (Pubitemid 26239093)
91. Goodman, M. J., Pearson, K. W., McGhie, D., Dutt, S. & Deodhar, S. G. Campylobacter and Giardia lamblia causing exacerbation of nflammatory bowel disease. Lancet 2, 1247 (1980). (Pubitemid 11250872)
92. Newman, A. & Lambert, J. R. Campylobacter jejuni causing flare-up in inflammatory bowel disease. Lancet 2, 919 (1980). (Pubitemid 10014333)
93. Kalischuk, L. D., Inglis, G. D. & Buret, A. G. Campylobacter jejuni induces transcellular translocation of commensal bacteria via lipid rafts. Gut Pathog. 1, 2 (2009).
94. Man, S. M. et al. Campylobacter concisus and other Campylobacter species in children with newly diagnosed Crohn's disease. Inflamm. Bowel Dis. 16, 1008-1016 (2010).
95. Zhang, L. et al. Isolation and detection of Campylobacter concisus from saliva of healthy ndividuals and patients with inflammatory bowel disease. J. Clin. Microbiol. 48, 2965-2967 (2010).
96. Istivan.T. S., Smith, S. C, Fry, B. N. & Coloe, P. J. Characterization of Campylobacter concisus hemolysins. FEMS Immunol. Med. Microbiol. 54, 224-235 (2008).
97. Istivan.T. S., Coloe, P. J., Fry, B. N., Ward, P. & Smith, S. C. Characterization of a haemolytic phospholipase A(2) activity in clinical isolates of Campylobacter concisus. J. Med. Microbiol. 53, 483-93 (2004). (Pubitemid 38803041)
98. Engberg, J. et al. Campylobacter concisus: an evaluation of certain phenotypic and genotypic characteristics. Clin. Microbiol. Infect 11, 288-295 (2005). (Pubitemid 40443834)
99. Kaakoush, N. O. et al. The secretome of Campylobacter concisus. FEBSJ. 277, 1606-1617 (2010).
100. Aabenhus, R., On, S. L., Siemer, B. L.Permin, H. & Andersen, L. P. Delineation of Campylobacter concisus genomospecies by amplified fragment length polymorphism analysis and correlation of results with clinical data. J. Clin. Microbiol. 43, 5091-5096 (2005). (Pubitemid 41484010)
101. Kalischuk, L. D. & Inglis, G. D. Comparative genotypic and pathogenic examination of Campylobacter concisus isolates from diarrheic and non-diarrheic humans. BMC Microbiol. 11, 53 (2011).
102. El-Omar, E. et al. Low prevalence of Helicobacter pylori in inflammatory bowel disease: association with sulphasalazine. Gut 35, 1385-1388 (1994). (Pubitemid 24310897)
103. Vare, P. O. et al. Seroprevalence of Helicobacter pylori infection in inflammatory bowel disease: is Helicobacter pylori infection a protective factor? Scand.J. Gastroenterol. 36, 1295-1300 (2001). (Pubitemid 33027809)
104. Feeney, M. A. et al. A case-control study of childhood environmental risk factors for the development of inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 14, 529-534 (2002). (Pubitemid 34518185)
105. Guslandi, M., Fanti, L. & Testoni, P. A. Helicobacter pylori seroprevalence in Crohn's disease: lack of nfluence by pharmacological treatment. Hepatogastroenterology 49, 1296-1297 (2002).
106. Luther, J., Dave, M., Higgins, P. D. & Kao, J. Y. Association between Helicobacter pylori infection and inflammatory bowel disease: a meta-analysis and systematic review of the literature. Inflamm. Bowel Dis. 16, 1077-1084 (2010).
107. Rad, R. et al. CD25+/Foxp3+T cells regulate gastric inflammation and Helicobacter pylori colonization in vivo. Gastroenterology 131, 525-537 (2006). (Pubitemid 44142446)
108. Luther, J. et al. Helicobacter pylori DNA decreases pro-inflammatory cytokine production by dendritic cells and attenuates dextran sodium sulphate-induced colitis. Gut 60, 1479-1486 (2011).
109. Elliott, D. E., Urban, J. J., Argo, C. K. & Weinstock, J. V. Does the failure to acquire helminthic parasites predispose to Crohn's disease? FASEBJ. 14, 1848-1855 (2000).
110. Mendall, M. A. et al. Childhood living conditions and Helicobacter pylori seropositivity in adult life. Lancet 339, 896-897 (1992).
111. Lemke, L. B. et al. Concurrent Helicobacter bilis nfection in C57BL/6 mice attenuates proinflammatory, H. py/ori-induced gastric pathology. Infect. Immun. 77, 2147-2158 (2009).
112. Hansen, R., Thomson, J. M., El-Omar, E. M. & Hold, G. L. The role of infection in the aetiology of nflammatory bowel disease. J. Gastroenterol. 45, 266-276 (2010).
113. Chalifoux, L. V. & Branson, R. T. Colonic adenocarcinoma associated with chronic colitis in cotton top marmosets, Saguinus oedipus. Gastroenterology 80, 942-946 (1981). (Pubitemid 11113034)
114. Cahill, R. J. et al. Inflammatory bowel disease: an immunity-mediated condition triggered by bacterial infection with Helicobacter hepaticus. Infect. Immun. 65, 3126-3131 (1997). (Pubitemid 27342388)
115. Kullberg, M. C. et al. Helicobacterhepaticus-nduced colitis in interleukin-10-deficient mice: cytokine requirements for the induction and maintenance of intestinal inflammation. Infect. Immun. 69, 4232-241 (2001). (Pubitemid 32574418)
116. Jergens, A. E. et al. Helicobacter bilis triggers persistent immune reactivity to antigens derived from the commensal bacteria in gnotobiotic C3H/HeN mice. Gut 56, 934-940 (2007). (Pubitemid 46999076)
117. Bell, S. J., Chisholm, S. A., Owen, R. J., Borriello, S. P. & Kamm, M. A. Evaluation of Helicobacter species in inflammatory bowel disease. Aliment. Pharmacol. Ther. 18, 481-486 (2003). (Pubitemid 37152288)
118. Grehan, M., Danon, S., Lee, A., Daskalopoulos, G. & Mitchell, H. Absence of mucosa-associated colonic Helicobacters in an Australian urban population. J. Clin. Microbiol. 42, 874-876 (2004). (Pubitemid 38222686)
119. Bohr, U. R. et al. Identification of enterohepatic Helicobacter species in patients suffering from nflammatory bowel disease. J. Clin. Microbiol. 42, 2766-2768(2004). (Pubitemid 38747533)
120. Thomson, J. M. et al. Enterohepatic Helicobacter in ulcerative colitis: potential pathogenic entities? PLoS ONE 6, el7184 (2011).
121. Zhang, L., Day, A., McKenzie, G. & Mitchell, H. Nongastric Helicobacter species detected in the ntestinal tract of children. J. Clin. Microbiol. AA, 2276-2279 (2006). (Pubitemid 43902194)
122. Man, S. M., Zhang, L, Day, A. S., Leach, S. & Mitchell, H. Detection of enterohepatic and gastric Helicobacter species in fecal specimens of children with Crohn's disease. Helicobacter 13, 234-238(2008).
123. Kaakoush, N. O. et al. Detection of Helicobacteraceae in intestinal biopsies of children with Crohn's disease. Helicobacter 15, 549-557 (2010).
124. Laharie, D. et al. Association between enterohepatic Helicobacter species and Crohn's disease: a prospective cross-sectional study. Aliment. Pharmacol. Ther. 30, 283-293 (2009).
125. Keenan, J. I. et al. Helicobacter species in the human colon. Colorectal Dis. 12, 48-53 (2008).
126. Hansen, R., Thomson, J. M., Fox, J. G., El-Omar, E. M. & Hold, G. L. Could Helicobacter organisms cause inflammatory bowel disease? FEMS Immunol. Med. Microbiol. 61, 1-14 (2011).
127. Wells, J. M., Rossi, O., Meijerink, M. & van Baarlen, P. Epithelial crosstalk at the microbiota-mucosal interface. Proc. Natl Acad. Sci. USA 108 (Suppl. 1), 4607-4614 (2011).
128. Hedayat, M., Netea, M. G. & Rezaei, N. Targeting of Toll-like receptors: a decade of progress in combating infectious diseases. Lancet Infect. Dis. 11, 702-712 (2011).
129. Kawai.T & Akira, S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34, 637-650 (2011).
130. Uematsu, S. & Fujimoto, K. The innate immune system in the intestine. Microbiol. Immunol. 54, 645-657 (2010).
131. Hold, G. L., Mukhopadhya, I. & Monie, T. P. Innate immune sensors and gastrointestinal bacterial nfections. Clin. Dev. Immunol. 2011, 579650 (2011).
132. Cullen, T. W. & Trent, M. S. A link between the assembly of flagella and lipooligosaccharide of the Gram-negative bacterium Campylobacter jejuni. Proc. Natl Acad. Sci. USA 107, 5160-5165 (2010).
133. Hold, G. L. & Bryant, C. E. in Bacterial Lipopolysaccharides: Structure, Chemical Synthesis, Biogenesis and Interaction with Host Cells (eds Knirel, Y. A. & Valvano, M. A.) 371-388 (Springer, New York, 2011).
134. Shen, X. et al. The Toll-like receptor 4 D299G and T399I polymorphisms are associated with Crohn's disease and ulcerative colitis: a metaanalysis. Digestion 81, 69-77 (2006).
135. Rallabhandi, P. et al. Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling. J. Immunol. 177, 322-332 (2006). (Pubitemid 43939144)
136. Arbour, N. C. et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet. 25, 187-191 (2000). (Pubitemid 30394990)
137. Kiechl, S. et al. Toll-like receptor 4 polymorphisms and atherogenesis. N. Engl. J. Med. 347, 185-192 (2002). (Pubitemid 34764822)
138. Lorenz, E., Mira, J. P., Frees, K. L. & Schwartz, D. A. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch. Intern. Med. 162, 1028-1032 (2002). (Pubitemid 34492532)
139. Eyking, A. et al. Toll-like receptor 4 variant D299G nduces features of neoplastic progression in Caco-2 intestinal cells and is associated with advanced human colon cancer. Gastroenterology 141, 2154-2165 (2011).
140. Fuse, K., Katakura, K., Sakamoto, N. & Ohira, H. Toll-like receptor 9 gene mutations and polymorphisms in Japanese ulcerative colitis patients. World J. Gastroenterol. 16, 5815-5821 (2010).
141. Hong, J. et al. TLR2, TLR4 and TLR9 polymorphisms and Crohn's disease in a New Zealand Caucasian cohort. J. Gastroenterol. Hepatol. 22, 1760-1766 (2007). (Pubitemid 47525075)
142. Torok, H. P. et al. Crohn's disease is associated with a toll-like receptor-9 polymorphism. Gastroenterology 127, 365-366 (2004).
143. Eaves-Pyles, T. et al. Escherichia coli isolated from a Crohn's disease patient adheres, invades, and nduces inflammatory responses in polarized ntestinal epithelial cells. Int. J. Med. Microbiol. 298, 397-09(2008) (Pubitemid 351734791)
144. Dasti, J. L., Tareen, A. M., Lugert, R., Zautner, A. E. & Gross, U. Campylobacter jejuni: a brief overview on pathogenicity-associated factors and disease-mediating mechanisms. Int. J. Med. Microbiol. 300, 205-211(2010).
145. Ohl, M. E. & Miller, S. I. Salmonella: a model for bacterial pathogenesis. Annu. Rev. Med. 52, 259-274 (2001). (Pubitemid 32195324)
146. Kelly, D. P. & Wood, A. P. Reclassification of some species of Thiobacillus to the newly designated genera Acidithiobacillus gen. nov., Halothiobacillus gen. nov. and Thermithiobacillus gen. nov. Int. J. Syst. Evol. Microbiol. 50 (Pt 2), 511-516 (2000). (Pubitemid 30167492)
147. Willing, B. P. et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 139, 1844-1854 el (2010).
148. Schwiertz, A. et al. Microbiota in pediatric nflammatory bowel disease. J. Pediatr. 157, 240-244 el (2010).
149. Thomazini, C. M., Samegima, D. A., Rodrigues, M. A., Victoria, C. R. & Rodrigues, J. High prevalence of aggregative adherent Escherichia coli strains in the mucosa-associated microbiota of patients with inflammatory bowel diseases. Int. J. Med. Microbiol. 301, 475-79 (2011).
150. Mondot, S. et al. Highlighting new phylogenetic specificities of Crohn's disease microbiota. Inflamm. Bowel Dis. 17, 185-192 (2011).
151. Gibson, G. R., Cummings, J. H. & Macfarlane, G. T. Growth and activities of sulphate-reducing bacteria in gut contents of healthy subjects and patients with ulcerative colitis. FEMS Microbiol. Lett. 86, 103-111 (1991).
152. Ternhag, A., Torner, A., Svensson, A., Ekdahl, K. & Giesecke, J. Short-and long-term effects of bacterial gastrointestinal infections. Emerg. Infect. Dis. 14, 143-148 (2008).